NT

Notable Labs LtdNASDAQ NTBL Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.006

Micro

Exchange

XNAS - Nasdaq

NTBL Stock Analysis

NT

Uncovered

Notable Labs Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-14/100

Low score

Market cap $B

0.006

Dividend yield

Shares outstanding

9.02 B

Notable Labs Ltd. engages in the development of predictive medicines for patients with cancer. The company is headquartered in Foster City, California and currently employs 16 full-time employees. The company went IPO on 2014-09-30. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

View Section: Eyestock Rating